BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14
07 sept. 2022 07h00 HE
|
BioRestorative Therapies, Inc
BioRestorative Therapies to highlight addition of Phase 2 clinical trial for chronic lumbar disc disease to its mid-stage pipeline. Melville, NY., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative...
AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients
26 juil. 2022 17h50 HE
|
Aisa Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the...
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
30 juin 2022 07h30 HE
|
BioRestorative Therapies, Inc
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
09 juin 2022 09h38 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
25 mai 2022 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including...
Throne Biotechnologies Launches Equity Crowdfunding to Support Phase 2 Clinical Trials in Type 1 Diabetes and Alopecia Areata
28 févr. 2022 09h00 HE
|
Throne Biotechnologies Inc
PARAMUS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their...
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
21 déc. 2021 16h01 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Enters into Letter of Intent with PRC Clinical
19 nov. 2021 06h00 HE
|
BioRestorative Therapies, Inc
PRC Clinical to Provide Start-up CRO Services for BRTX-100 Phase 2 Clinical Trial MELVILLE, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or...
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
28 sept. 2021 08h00 HE
|
First Wave BioPharma, Inc.
Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory...
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant
16 août 2021 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast...